Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 3/20 | 0.36 |
| ▸ | GUSB | P08236 | 4/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 5/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 5/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 5/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | CCND2 | P30279 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26807476 | 0.94 | ALOX12 (0.36) | HTR6RIPK2ACVR1NOD2CDK4 | |
| SCHEMBL26807471 | 0.94 | ACVR1 (0.40) | FLT3HTR6GUSBRIPK2ACVR1 | |
| SCHEMBL24310583 | 0.93 | RIPK2 (0.38) | FLT3HTR6GUSBRIPK2ACVR1 | |
| SCHEMBL26809994 | 0.91 | GUSB (0.36) | FLT3HTR6GUSBRIPK2ACVR1 | |
| SCHEMBL26807728 | 0.90 | FLT3 (0.37) | FLT3HTR6GUSBRIPK2ACVR1 | |
| SCHEMBL26807316 | 0.88 | RIPK2 (0.39) | FLT3HTR6GUSBRIPK2ACVR1 | |
| SCHEMBL29566726 | 0.88 | RIPK2 (0.39) | FLT3HTR6GUSBRIPK2ACVR1 | |
| SCHEMBL26858387 | 0.87 | GUSB (0.42) | HTR6GUSB | |
| SCHEMBL26807460 | 0.87 | HTR6 (0.43) | FLT3HTR6GUSBRIPK2ACVR1 | |
| SCHEMBL29566834 | 0.86 | HTR6 (0.38) | FLT3HTR6GUSBRIPK2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-4225748-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | FLT3 4133/4885HTR6 2653/4885GUSB 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.